Summary

Hypercalcemia is a common end-stage problem in patients with malignant neoplasms. Malignancy is the most common cause of hypercalcemia in hospitalized patients, whereas primary hyperparathyroidism is the most common cause of hypercalcemia in nonhospitalized patients. PTHrP is the most common cause of hypercalcemia in patients with cancer. There are now PTHrP assays to quantitate PTHrP levels. Unfortunately, there are no good means of treating patients with malignant tumors and high PTHrP levels, and most patients die within 8 weeks.

REFERENCES

1. Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: Changes in the pattern of clinical presentation. Lancet 1980; 1:1317.

2. Fisken RA, Heath DA, Bold AM. Hypercalcaemia—A hospital survey. Q J Med 1980:49:405.

3. Zondek H, Petow H, Siebert W. Die bedeutung der calciumbestimmung im blute fur die diagnose der niereninsuffizientz. Z Klin Med 1924; 99:129.

4. Case records of the Massachusetts General Hospital. Case 27461. N Engl J Med 1941;225:789.

5. Broadus AE, Mangin M, Ikeda K, et al. Humoral hypercalcemia of cancer: Identification of a novel parathyroid hormone-like peptide. N Engl J Med 1988:319:556.

6. Strewler GJ, Nissenson RA. Hypercalcemia in malignancy. West J Med 1990:153:635.

7. Ralston SH, Gallacher SJ, Patel U, et al. Cancer-associated hypercalcemia: Morbidity and mortality. Ann Intern Med 1990; 112:499.

8. Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma. Ann Intern Med 1974;80:205.

9. Broadus A, Stewart A. Parathyroid hormone-related protein: Structure, processing, and physiological actions. In: Bilezikian J, Levine M, Marcus R (eds), The Parathyroids. New York, Raven Press, 1994, p 259.

10. Orloff JJ, Reddy D, de Papp AE, et al. Parathyroid hormone-related protein as a prohormone: Posttranslational processing and receptor interactions. Endocr Rev 1994; 15:40.

11. Budayr AA, Nissenson RA, Klein RF, et al. Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989;111:807.

12. Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;322:1106.

13. Grill V, Ho P, Body JJ, et al. Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991:73:1309.

14. Ratcliffe WA, Norbury S, Stott RA, et al. Immunoreactivity of plasma parathyrin-related peptide: Three region-specific radioimmunoassays and a two-site immunoradiometric assay compared. Clin Chem 1991:37:1781.

15. Blind E, Raue F, Gotzmann J, et al. Circulating levels of midregional parathyroid hormone-related protein in hypercalcaemia of malignancy. Clin Endocrinol (Oxf) 1992:37:290.

16. Fukumoto S, Matsumoto T, Ikeda K, et al. Clinical evaluation of calcium metabolism in adult T-cell leukemia/lymphoma. Arch Intern Med 1988:148:921.

17. Watanabe T, Yamaguchi K, Takatsuki K, et al. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be transactivated by HTLV-1 tax gene. J Exp Med 1990:172:759.

18. Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: Evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994:79:1322.

19. Dittmer J, Gitlin SD, Reid RL, et al. Transactivation of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus type I Taxi: Evidence for the involvement of transcription factor EtslJ Virol 1993:67:6087.

20. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res 1991:51:3059.

21. Guise TA, Taylor SD, Yoneda T, et al. Parathyroid hormone-related protein (PTHrP) expression by breast cancer cells enhanced osteolytic bone metastases in vivo [Abstract], J Bone Miner Res 1994;9:S128.

22. Kimura S, Nishimura Y, Yamaguchi K, et al. A case of pheochromocy-toma producing parathyroid hormone-related protein and presenting with hypercalcemia. J Clin Endocrinol Metab 1990:70:1559.

23. Mune T, Katakami H, Kato Y, et al. Production and secretion of parathyroid hormone-related protein in pheochromocytoma: Participation of an alpha-adrenergic mechanism. J Clin Endocrinol Metab 1993;76:757.

24. Lepre F, Grill V, Ho PW, et al. Hypercalcemia in pregnancy and lactation associated with parathyroid hormone-related protein [Letter]. N Engl J Med 1993:328:666.

25. Braude S, Graham A, Mitchell D: Lymphoedema/hypercalcaemia syndrome mediated by parathyroid-hormone-related protein. Lancet 1991:337:140.

26. Strewler GJ, Nissenson RA. The parathyroid hormone-related protein as a regulator of normal tissue functions. In: Kohler PO (ed), Current Opinion in Endocrinology and Diabetes. Philadelphia, Current Science, 1994, p 286.

27. Karaplis AC, Luz A, Glowacki J, et al. Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 1994:8:277.

28. Wysolmerski JJ, Broadus AE, Zhou J, et al. Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development. Proc Natl Acad Sci USA 1994;91:1133.

29. Wysolmerski JJ, McCaughern-Carucci JF, Daifotis AG, et al. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development 1995:121:3539.

30. Budayr AA, Halloran BP, King JC, et al. High levels of a parathyroid hormone-like protein in milk. Proc Natl Acad Sci USA 1989; 86:7183.

31. Hongo T, Kupfer J, Enomoto H, et al. Abundant expression of parathyroid hormone-related protein in primary rat aortic smooth muscle cells accompanies serum-induced proliferation. J Clin Invest 1991:88:1841.

32. Yamamoto M, Harm SC, Grasser WA, et al. Parathyroid hormone-related protein in the rat urinary bladder: A smooth muscle relaxant produced locally in response to mechanical stretch. Proc Natl Acad Sci USA 1992;89:5326.

33. Thiede MA, Daifotis AG, Weir EC, et al. Intrauterine occupancy controls expression of the parathyroid hormone-related peptide. Proc Natl Acad Sci USA 1990;87:6969.

34. Winquist RJ, Baskin EP, Vlasuk GP. Synthetic tumor-derived human hypercalcemic factor exhibits parathyroid hormone-like vasorelaxation in renal arteries. Biochem Biophys Res Commun 1987; 149:227.

35. Nickols GA, Nickols MA, Helwig JJ. Binding of parathyroid hormone and parathyroid hormone-related protein to vascular smooth muscle of rabbit renal microvessels. Endocrinology 1990;126:721.

36. Mok LL, Cooper CW, Thompson JC. Parathyroid hormone and parathyroid hormone-related protein inhibit phasic contraction of pig duodenal smooth muscle. Proc Soc Exp Biol Med 1989:191:337.

37. Seymour JF, Gagel RF. Calcitriol: The major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993;82:1383.

38. Adams JS, Fernandez M, Gacad MA, et al. Vitamin D metabolite-mediated hypercalcemia and hypercalciuria patients with AIDS and non-AIDS-associated lymphoma. Blood 1989:73:235.

39. Seymour JF, Gagel RF, Hagemeister FB, et al. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 1994:121:633.

40. Davies M, Hayes ME, Yin JA, et al. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 1994;78:1202.

41. Barbour GL, Coburn JW, Slatopolsky E, et al. Hypercalcemia in an anephric patient with sarcoidosis: Evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med 1981;305:440.

42. Stern PH, De Olazabal J, Bell NH. Evidence for abnormal regulation of circulating 1 alpha, 25-dihydroxyvitamin D in patients with sarcoidosis and normal calcium metabolism. J Clin Invest 1980;66:852.

43. Strewler GJ, Budayr AA, Clark OH, et al. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993:76:1373.

44. Yoshimoto K, Yamasaki R, Sakai H, et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989;68:976.

45. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma. N Engl J Med 1990;323:1324.

46. Brereton HD, Halushka PV, Alexander RW, et al. Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma. N Engl J Med 1974;291:83.

47. Mundy G. Hypercalcemic factors other than parathyroid hormone-related protein. Endocrinol Metab Clin North Am 1989:18:795.

48. Kawano M, Yamamoto I, Iwato K, et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 1989:73:1646.

49. Garrett IR, Durie BGM, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma. N Engl J Med 1987:317:526.

50. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987:33:1364.

51. Wimalawansa SJ. Significance of plasma PTHrP in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994:73:2223.

52. Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990:322:1106.

53. Fraser WD, Robinson J, Lawton R, et al. Clinical and laboratory studies of a new immunoradiometric assay of parathyroid hormone-related protein. Clin Chem 1993;39:414.

54. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992:326:1196.

55. Nussbaum SR. Pathophysiology and management of severe hypercalcemia. Endocrinol Metab Clin North Am 1993:22:343.

56. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of Pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134.

57. Nussbaum SR, Younger J, VandePol CJ, et al. Single-dose intravenous therapy with Pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95:297.

58. Dodwell DJ, Abbas SK, Morton AR, et al. Parathyroid hormone-related protein (50-69) and response to Pamidronate therapy for tumour-induced hypercalcaemia. Eur J Cancer 1991 ;27:1629.

59. Body JJ, Dumon JC, Thirion M, et al. Circulating PTHrP concentrations in tumor-induced hypercalcemia: Influence on the response to bisphosphonate and changes after therapy. J Bone Miner Res 1993:8:701.

60. Budayr AA, Zysset E, Jenzer A, et al. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res 1994;9:521.

fg.i r chapter 62

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment